Group 1 - The A-share innovative drug sector experienced a strong rebound, with the Biopharmaceutical ETF (159839) rising by 4.17% and a trading volume exceeding 44 million yuan [1] - The Biopharmaceutical ETF (159839) has seen a net inflow of over 15 million yuan for two consecutive days [1] - Several innovative drug companies reported significant stock price increases, with notable gains including 9.99% for Zhaoyan New Drug and 7.53% for Changchun High-tech [2] Group 2 - The pharmaceutical industry is experiencing structural differentiation, with a 0.7% decline in revenue and a 1.5% increase in net profit for listed companies in the first half of 2025 [3] - Leading innovative drug companies are achieving profitability, driven by strong sales of key products such as Zebutinib and Furmetinib [3] - The innovative drug sector is expected to benefit from improved policies and a downward trend in global central bank interest rates, which may enhance long-term valuations [4] Group 3 - The CXO industry is entering a recovery phase, with a resurgence in overseas demand expected by the end of 2023, leading to a recovery in domestic head companies' orders in 2024 [5] - The domestic innovative drug assets are progressing into late clinical stages, with increasing validation of clinical data and a clear trend towards internationalization [5]

Core Viewpoint - The medical services sector experienced a significant increase of 3.79% on September 5, with Zhaoyan New Drug leading the gains [1] Market Performance - The Shanghai Composite Index closed at 3812.51, up 1.24% - The Shenzhen Component Index closed at 12590.56, up 3.89% [1] Individual Stock Performance - Zhaoyan New Drug (603127) closed at 34.01, up 9.99% with a trading volume of 578,000 shares and a transaction value of 1.905 billion yuan - Tiger Medical (300347) closed at 66.58, up 6.66% with a trading volume of 146,300 shares and a transaction value of 950 million yuan - Kailaiying (002821) closed at 108.27, up 6.44% with a trading volume of 114,500 shares and a transaction value of 1.213 billion yuan - Posens (301257) closed at 49.20, up 5.81% with a trading volume of 84,700 shares and a transaction value of 407 million yuan - Kanglong Chemical (300759) closed at 31.30, up 5.56% with a trading volume of 615,400 shares and a transaction value of 1.887 billion yuan - WuXi AppTec (603259) closed at 107.40, up 5.36% with a trading volume of 802,300 shares and a transaction value of 8.39 billion yuan - Jiuzhou Pharmaceutical (603456) closed at 19.15, up 5.22% with a trading volume of 441,000 shares and a transaction value of 827 million yuan - ST Biological (000504) closed at 9.68, up 4.99% with a trading volume of 49,800 shares and a transaction value of 4.749 million yuan - Nossger (301333) closed at 58.02, up 4.94% with a trading volume of 56,100 shares and a transaction value of 32.2 million yuan - Boteng Co., Ltd. (300363) closed at 25.90, up 4.73% with a trading volume of 396,800 shares and a transaction value of 1.011 billion yuan [1] Capital Flow - The medical services sector saw a net inflow of 423 million yuan from institutional investors, while retail investors experienced a net outflow of 58.5864 million yuan [1]

Market Overview - The Hong Kong stock market indices collectively rose, with the Hang Seng Index increasing by 1.43% to 25,417.98 points, the Hang Seng China Enterprises Index up by 1.34%, and the Hang Seng Tech Index rising by 1.95% [1][2]. Technology Sector - Major technology stocks saw significant gains, with Kuaishou rising over 4%, Tencent Holdings up more than 2%, and JD Group, Meituan, Alibaba, NetEase, and Baidu all increasing by over 1% [2][3]. Wind Power Sector - Wind power stocks led the market with Goldwind Technology surging over 18%, followed by other companies like Longyuan Power and Datang Renewable Energy also showing gains [5][6]. Semiconductor Sector - Semiconductor and chip stocks strengthened, with Horizon Robotics increasing over 9%, and other companies like Globalfoundries and SMIC also experiencing gains [6][7]. Gold Sector - Gold stocks rose, with Tongguan Gold increasing nearly 6%, and other companies such as Shandong Gold and Zijin Mining also showing positive performance [8][9]. Lithium Battery Sector - The lithium battery sector was active, with Zhongchuang Innovation rising over 18%, and companies like Tianqi Lithium and Ningde Times also seeing significant increases [10][11]. Pharmaceutical Outsourcing Sector - The pharmaceutical outsourcing sector rebounded, with Zhaoyan New Drug rising nearly 9%, and other firms like Kanglong Chemical and Tigermed also reporting gains [12][13]. Solar Energy Sector - Solar energy stocks surged, with GCL-Poly Energy increasing over 26%, and other companies like Sunshine Energy and New Special Energy also performing well [14][15]. Agricultural Products Sector - The agricultural products sector declined, with Hualian International dropping nearly 30%, and other related stocks also experiencing losses [16][17]. Company Performance - Ark Health recently reported a revenue of 1.494 billion, a year-on-year increase of 12.9%, and a net profit turnaround to 12.5 million, reflecting significant progress in its main business [21].

Group 1 - The CRO (Contract Research Organization) concept stocks in the A-share market have shown strong performance, with notable gains in several companies [1] - Zhaoyan New Drug approached the daily limit increase with a rise of 9.12%, while other companies like Kailaiying, Nossger, and Kanglong Chemical also saw increases exceeding 5% [1][2] - The total market capitalization of Zhaoyan New Drug is 25.3 billion, and it has achieved a year-to-date increase of 103.06% [2] Group 2 - Kailaiying's stock rose by 5.48%, with a total market capitalization of 38.7 billion and a year-to-date increase of 42.84% [2] - Nossger and Kanglong Chemical experienced increases of 5.44% and 5.19%, respectively, with market capitalizations of 5.631 billion and 55.5 billion [2] - Other companies such as Sunshine Nuohuo and Boteng also reported gains of over 5%, with year-to-date increases of 109.05% and 64.55% respectively [2]

特此公告。 北京昭衍新药研究中心股份有限公司董事会 | 证券代码：603127 证券简称：昭衍新药 公告编号：2025-038 | | | | | --- | --- | --- | --- | | 北京昭衍新药研究中心股份有限公司 | | | | | A 股股份计划期限届满暨减持结果公告 | 关于股东减持 | | | | 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 | | | | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | | | 重要内容提示： | | | | | 股东持股的基本情况 | ? | | | | 北京昭衍新药研究中心股份有限公司（下称"公司"）股东原副董事长左从林 | | | | | 2025 年 8 月 14 日披露减持计划前，持有公司股份 14,098,317 股， | （已离任）在 | | | | 1.8811%。上述股份来源于首发前限售股份、公司资本公积金转增股 | 持股比例为 | | | | 份等其他方式。 | | | | | 减持计划的实施结果情况 | ? | | | | 2025 年 8 月 14 日披露了减持 ...

昭衍新药（603127）(06127)发布公告，公司股东原副董事长左从林于2025年8月14日披露了减持计划， 自减持计划公告之日起3个交易日后即2025年8月19日至2025年8月29日内通过上海证券交易所集中竞价 或大宗交易的方式减持不超过352.45万股，减持比例不超过公司当时总股本的0.4703%。截至2025年8月 29日，左从林以集中竞价的方式减持了公司A股股份226.49万股，减持计划时间届满。 ...

北京昭衍新药研究中心股份有限公司 关于股东减持 A 股股份计划期限届满暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 北京昭衍新药研究中心股份有限公司（下称"公司"）股东原副董事长左从林 （已离任）在 2025 年 8 月 14 日披露减持计划前，持有公司股份 14,098,317 股， 持股比例为 1.8811%。上述股份来源于首发前限售股份、公司资本公积金转增股 份等其他方式。 减持计划的实施结果情况 证券代码：603127 证券简称：昭衍新药 公告编号：2025-038 二、减持计划的实施结果 (一)股东因以下事项披露减持计划实施结果： 披露的减持时间区间届满 | 股东名称 | 左从林 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 减持计划首次披露日期 | 年 2025 8 | 月 | 14 | 日 | | | | | 减持数量 | 2,264,900股 | | | | | ...

Core Viewpoint - The announcement details a share reduction plan by the former vice chairman of Zhaoyan New Drug, indicating a potential shift in shareholder sentiment and possible implications for the company's stock performance [1] Summary by Relevant Sections Share Reduction Plan - The former vice chairman, Zuo Conglin, disclosed a share reduction plan on August 14, 2025, intending to reduce holdings between August 19 and August 29, 2025 [1] - The plan allows for a maximum reduction of 3.5245 million shares, which represents up to 0.4703% of the company's total share capital at that time [1] Execution of the Plan - By the end of the reduction period on August 29, 2025, Zuo Conglin had reduced his holdings by 2.2649 million shares through centralized bidding [1]

| FF301 | | | | | | --- | --- | --- | --- | --- | | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | | | | 截至月份: 2025年8月31日 | | | | 狀態: 新提交 | | 致：香港交易及結算所有限公司 | | | | | | 公司名稱: 北京昭衍新藥研究中心股份有限公司 | | | | | | 呈交日期: 2025年9月1日 | | | | | | I. 法定/註冊股本變動 | | | | | | (如上市) 06127 證券代號 | | | | | | 法定/註冊股份數目 | | | | 面值 法定/ | | 註冊股本 | | | | | | 上月底結存 118,995,206 RMB | | | | 1 | | RMB 118,995,206 | | | | | | 增加 / 減少 (-) 0 | | | | | | RMB | | | | | | 本月底結存 118,995,206 RMB | | | | 1 | | RMB 118,995,206 | | | | | | 603127 證券代號 ...

海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年9月1日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 ...